The Rise of AI in Sleep Medicine

By Ann H. Carlson When it comes to an individual patient’s treatment plan for sleep disorders, the more data, the better. A single polysomnogram (PSG) provides invaluable information to help diagnose and treat one specific patient, but scientists have long understood that comparing hundreds—or even thousands—of tests can help identify otherwise undiscovered patterns across the…

Read More

Philips: Sleep Therapy Devices Pass Ozone Cleaning Analysis

Philips Respironics provided the latest results and conclusions on the comprehensive test and research program to assess potential health risks related to the polyester-based polyurethane (PE-PUR) sound abatement foam in specific sleep therapy and ventilator devices under the voluntary June 2021 recall notification/field safety notice.  Philips completed the analyses for System One and DreamStation Go…

Read More

Chatbots Can Help Boost Your Sleep

Researchers at the University of South Australia have found that chatbots are an effective tool to significantly improve sleep, along with physical activity and diet. The systematic review and meta-analysis, published in Nature Digital Medicine, found that chatbots—otherwise known as conversational agents or virtual assistants—can quickly and capably support you to improve sleep duration and…

Read More

BRPT Announces A-STEP/STAR Educational Grant Winner

The Board of Registered Polysomnographic Technologists (BRPT) announced Henry Stabenau from Eau Claire, Wis, as the winner of its A-STEP/STAR Educational Grant Program.  The program is for individuals interested in pursuing a career in sleep technology and/or those who are currently working as sleep technicians who would like to become a registered polysomnographic technologist (RPSGT).…

Read More

Axsome to Initiate Phase 3 Study of Solriamfetol for Shift Work Disorder 

In its second-quarter business highlights, Axsome Therapeutics Inc provided updates on a new potential indication for solriamfetol for shift work disorder, announced progress for its narcolepsy drug candidate, and revealed positive results from the Q2 relaunch of Sunosi. Solriamfetol is Axsome’s dopamine and norepinephrine reuptake inhibitor and TAAR1 agonist in development for the treatment of…

Read More